newsfilter
← Latest News
GlobeNewswire·

POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Enrollment in PNT2002's SPLASH trial is complete and topline data is expected in the fourth quarter of 2023 Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first patient dosed